NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
Public ClinicalTrials.gov record NCT07305818. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Study identification
- NCT ID
- NCT07305818
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- MER511 (IV) Biological
- Placebo comparator (IV) Biological
- MER511 (SC) Biological
- Placebo comparator (SC) Biological
- MER511 (SC) for MAD Biological
- Placebo comparator (SC) for MAD Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2025
- Primary completion
- Jul 23, 2028
- Completion
- Jul 23, 2028
- Last update posted
- Aug 23, 2026
2025 – 2028
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site # 1111 | Torrance | California | 90502 | Recruiting |
| Site # 1101 | Hollywood | Florida | 33024 | Recruiting |
| Site # 1112 | Miami | Florida | 33125 | Recruiting |
| Site # 1109 | Wesley Chapel | Florida | 33544 | Recruiting |
| Site # 1107 | Boston | Massachusetts | 02114 | Recruiting |
| Site # 1102 | Rochester | Minnesota | 55905 | Recruiting |
| Site # 1106 | Morehead City | North Carolina | 28557 | Recruiting |
| Site # 1104 | Columbus | Ohio | 43203 | Recruiting |
| Site # 1108 | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Site # 1113 | DeSoto | Texas | 75115 | Recruiting |
| Site # 1105 | Webster | Texas | 77598 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07305818, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07305818 live on ClinicalTrials.gov.